Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.39 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | GLI1 | P08151 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL801077 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL14443285 | 1.00 | NOS2 (0.43) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL26780565 | 0.94 | FDPS (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL420953 | 0.94 | FDPS (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL420946 | 0.94 | FDPS (0.38) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL23720635 | 0.89 | — | — | |
| SCHEMBL421836 | 0.89 | — | — | |
| SCHEMBL22436137 | 0.89 | — | — | |
| Trifluoroacetic Acid SCHEMBL5411611 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| Trifluoroacetic Acid SCHEMBL5411607 | 0.88 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | RMW CHO GROUP LIMITED (HK) | 2023-11-16 | — | — | US | disclosed |
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | PHARMA MAR, S.A. (ES) | 2023-05-25 | — | — | US | disclosed |
| WO-2023086557-A1 | NUCLEOSIDES FOR THE TREATMENT OF DNA VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | THE UNIVERSITY OF SHEFFIELD (GB) | 2023-02-02 | — | — | US | disclosed |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | UNIV DREXEL (US) | 2022-12-08 | — | — | US | disclosed |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2022-05-17 | — | — | US | disclosed |
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | BARCLAYS BANK PLC (GB) | 2022-01-20 | — | — | US | disclosed |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-20 | — | — | US | disclosed |
| WO-2009061597-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | SCHERING CORPORATION (US) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | ENANTA PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2009-03-19 | — | — | US | disclosed |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2009-03-12 | — | — | US | disclosed |
| EP-1627880-B1 | Boronic ester and acid compounds, synthesis and uses | MILLENNIUM PHARM INC (US) | 2008-10-15 | — | — | EP | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| US-7304078-B2 | Thrombosis; cardiovascular disorders; restenosis; hypotensive agents; antiarrhythmia agents; antiinflamamtroy agents; central nervous system disorders | SCHERING CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| US-20070270439-A1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2007-11-22 | — | — | US | disclosed |
| US-20070179187-A1 | THROMBIN RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2007-08-02 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075915-A1 | 6,11-BICYCLOLIDES: BRIDGED BIARYL MACROLIDE DERIVATIVES | CYP2B6, ABCB11, CYP2D6 | NOS2 1750/4885NOS3 1746/4885NOS1 2820/4885 |
| US-11331331-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | ENTPD1, NME2, NME1 | NOS2 1898/4885NOS3 1753/4885NOS1 1633/4885 |
| US-20230159594-A1 | COMPOUNDS FOR USE IN VIRAL INFECTIONS | OAT, MAVS, HAVCR2 | NOS2 1660/4885NOS3 1045/4885NOS1 2059/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | NOS2 3457/4885NOS3 2093/4885NOS1 3677/4885 |
| US-20090068140-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, PYGL, HCCS | NOS2 3457/4885NOS3 2093/4885NOS1 3677/4885 |
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | PMM2, DPM1, BPGM | NOS2 2106/4885NOS3 2746/4885NOS1 2181/4885 |
| US-20220016153-A1 | N4-HYDROXYCYTIDINE AND DERIVATIVES AND ANTI-VIRAL USES RELATED THERETO | ENTPD1, NME2, NME1 | NOS2 1898/4885NOS3 1753/4885NOS1 1633/4885 |
| US-20230348518-A1 | HELICASE INHIBITORS FOR TREATMENT OF MEDICAL DISORDERS | RECQL, DDX21, DDX41 | NOS2 4636/4885NOS3 4653/4885NOS1 4572/4885 |
| US-20090118506-A1 | 6,11-BRIDGED BIARYL MACROLIDES | CYP2B6, CYP2D6, ABCB11 | NOS2 1639/4885NOS3 1939/4885NOS1 2843/4885 |
| US-20070179187-A1 | THROMBIN RECEPTOR ANTAGONISTS | TBXA2R, BDKRB2, AGTR2 | NOS2 2674/4885NOS3 1047/4885NOS1 3548/4885 |
| US-20220388980-A1 | QUINOLINE INHIBITORS OF RAD52 AND METHODS OF USE | RAD52, RECQL, RAD50 | NOS2 3254/4885NOS3 4403/4885NOS1 3977/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | NOS2 306/4885NOS3 238/4885NOS1 271/4885 |
| US-20070270439-A1 | THROMBIN RECEPTOR ANTAGONISTS | TBXA2R, BDKRB2, AGTR2 | NOS2 2597/4885NOS3 1001/4885NOS1 3461/4885 |
| US-20230036854-A1 | HETEROCYCLIC SPIRO-COMPOUNDS AS AM2 RECEPTOR INHIBITORS | MC2R, AGTR2, NR3C2 | NOS2 1066/4885NOS3 1151/4885NOS1 1905/4885 |
| US-20230365577-A1 | Photodynamic Therapy and Diagnosis | PPOX, PPIF, ALAD | NOS2 3480/4885NOS3 4008/4885NOS1 4309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.